X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
index medicus (32) 32
pharmacology & pharmacy (23) 23
male (21) 21
female (18) 18
schizophrenia (17) 17
adult (15) 15
antipsychotic agents - pharmacokinetics (15) 15
pharmacology (15) 15
pharmacology/toxicology (15) 15
pharmacokinetics (14) 14
middle aged (13) 13
models, biological (11) 11
adolescent (10) 10
aged (10) 10
biomedicine (10) 10
schizophrenia - drug therapy (10) 10
antipsychotic agents - adverse effects (9) 9
asenapine (9) 9
biochemistry, general (9) 9
dose-response relationship, drug (9) 9
pharmacy (9) 9
young adult (9) 9
biomedical engineering (8) 8
computer simulation (8) 8
heterocyclic compounds, 4 or more rings - pharmacokinetics (8) 8
antipsychotic agents - administration & dosage (7) 7
antipsychotic agents - therapeutic use (7) 7
cross-over studies (7) 7
drug therapy (7) 7
efficacy (7) 7
heterocyclic compounds, 4 or more rings - adverse effects (7) 7
analysis (6) 6
animals (6) 6
care and treatment (6) 6
internal medicine (6) 6
models (6) 6
psychiatry (6) 6
safety (6) 6
antipsychotic agents - blood (5) 5
antipsychotic drugs (5) 5
biotechnology (5) 5
chemistry, multidisciplinary (5) 5
double-blind (5) 5
heterocyclic compounds, 4 or more rings - administration & dosage (5) 5
history (5) 5
medical law (5) 5
medicine & public health (5) 5
patients (5) 5
pharmacotherapy (5) 5
placebo effect (5) 5
psychiatric status rating scales (5) 5
receptors, dopamine d2 - metabolism (5) 5
time factors (5) 5
aged, 80 and over (4) 4
antipsychotic agents - pharmacology (4) 4
brain - metabolism (4) 4
dopamine (4) 4
dopamine d-2 receptor occupancy (4) 4
double-blind method (4) 4
drugs (4) 4
mathematical models (4) 4
mechanism-based pk-pd (4) 4
molecular medicine (4) 4
nonlinear dynamics (4) 4
olanzapine (4) 4
oncology (4) 4
organic chemistry (4) 4
patient dropouts (4) 4
pembrolizumab (4) 4
pharmaceutical science (4) 4
rats (4) 4
research (4) 4
treatment outcome (4) 4
acute mania (3) 3
administration, oral (3) 3
administration, sublingual (3) 3
antipsychotic (3) 3
area under curve (3) 3
atypical antipsychotics (3) 3
belgium (3) 3
body weight (3) 3
brain - drug effects (3) 3
cells (3) 3
clinical trials as topic (3) 3
dopamine d2 receptor occupancy (3) 3
dropout model (3) 3
drug interactions (3) 3
exposure (3) 3
health aspects (3) 3
heterocyclic compounds, 4 or more rings - blood (3) 3
in-vitro (3) 3
kinetics (3) 3
metabolites (3) 3
modelling (3) 3
models, statistical (3) 3
models, theoretical (3) 3
pharmacodynamics (3) 3
placebo-controlled trial (3) 3
population (3) 3
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (68) 68
Dutch (9) 9
French (7) 7
German (2) 2
Frisian (1) 1
Italian (1) 1
Latin (1) 1
Portuguese (1) 1
Spanish (1) 1
Western (1) 1
Western Frisian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal for immunotherapy of cancer, ISSN 2051-1426, 08/2019, Volume 7, Issue 1, pp. 212 - 8
Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in... 
Immunogenetics | Research | Gene expression | Apoptosis | Efficacy | Advanced tumors | Pembrolizumab | Treatment-emergent ADA | Safety | Immunogenicity
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 31, pp. 3889 - +
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2014, Volume 31, Issue 10, pp. 2605 - 2617
Objectives Dopamine D-2 receptor occupancy (D2RO) is the major determinant of efficacy and safety in schizophrenia drug therapy. Excessive D2RO (>80%) is known... 
catalepsy | CLOZAPINE | RESPONSES | MECHANISM | ANTIPSYCHOTIC-DRUGS | EPS | dopamine D-2 receptor antagonist | Markov model | schizophrenia | PET | Biochemistry, general | Biomedical Engineering | dopamine D 2 receptor antagonist | Biomedicine | Pharmacy | Medical Law | Pharmacology/Toxicology | PHARMACOLOGY & PHARMACY | CHEMISTRY, MULTIDISCIPLINARY | Catalepsy - etiology | Markov Chains | Antipsychotic Agents - adverse effects | Humans | Risperidone - pharmacokinetics | Catalepsy - metabolism | Receptors, Dopamine D2 - metabolism | Brain - metabolism | Dose-Response Relationship, Drug | Computer Simulation | Risperidone - adverse effects | Isoxazoles - pharmacokinetics | Severity of Illness Index | Benzodiazepines - pharmacology | Paliperidone Palmitate | Risperidone - pharmacology | Rats | Dopamine D2 Receptor Antagonists - pharmacokinetics | Benzodiazepines - pharmacokinetics | Antipsychotic Agents - pharmacokinetics | Pyrimidines - pharmacology | Isoxazoles - pharmacology | Animals | Models, Biological | Pyrimidines - adverse effects | Dopamine D2 Receptor Antagonists - pharmacology | Pyrimidines - pharmacokinetics | Benzodiazepines - adverse effects | Antipsychotic Agents - pharmacology | Dopamine D2 Receptor Antagonists - adverse effects | Isoxazoles - adverse effects | Schizophrenia | Markov processes | Phenols | Dopamine | Antipsychotic drugs | Side effects | Pharmacology | Drug therapy | Rodents
Journal Article
Journal of Pharmacokinetics and Pharmacodynamics, ISSN 1567-567X, 10/2017, Volume 44, Issue 5, pp. 403 - 414
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 2677 - 2693
Journal Article
Journal Article
Journal Article